Led jointly by King’s College London and Janssen Pharmaceutica NV, RADAR-CNS brings together some of the leading clinicians, researchers, device engineers, computer scientists, and data analysts from 24 organisations across Europe and USA.
The aim is to build an infrastructure for collecting and processing data from mobile devices to identify clinically useful biomarkers that predict relapse or deterioration (eg, changes in sleep, physical activity, cognition, memory). For example, in depression, people’s behaviour may change even before they have noticed they are struggling (their sleep may be getting worse, or they may have reduced their activity in the weeks before a relapse).
Patients are involved in RADAR-CNS from the start—helping to identify the most important symptoms to target, and helping to design and develop user-friendly, secure technologies. Wherever possible, the researchers aim to use inexpensive and widely available technology, so that the end results can be made available to as many people as possible.
RADAR-CNS is a major step in developing new ways of monitoring brain disorders. Ultimately, this will improve patients’ quality of life and make treatments more effective. The research is also being developed in a way that allows the technology to be adapted for use in other diseases like bipolar disorder and Alzheimer’s disease, and could have a big impact on healthcare in the future.